TNFSF13B and systemic lupus erythematosus: Another BLyS inhibitor under investigation is Tabalumab, however, a major SLE study was terminated early as the endpoint was not reached (NCT02041091) and a large study regarding RA showed neither clinical efficacy nor relevant safety events [194].